Immunitybio Operating Margin vs. Number Of Shares Shorted

IBRX Stock  USD 4.74  0.18  3.95%   
Considering Immunitybio's profitability and operating efficiency indicators, Immunitybio may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Immunitybio's ability to earn profits and add value for shareholders.

Immunitybio Operating Profit Margin

(611.52)

At this time, Immunitybio's Price To Sales Ratio is fairly stable compared to the past year. EV To Sales is likely to rise to 7,001 in 2024, whereas Days Sales Outstanding is likely to drop 1,766 in 2024. At this time, Immunitybio's Accumulated Other Comprehensive Income is fairly stable compared to the past year. Net Income Per E B T is likely to rise to 1.10 in 2024, despite the fact that Operating Income is likely to grow to (344.1 M).
For Immunitybio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immunitybio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immunitybio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immunitybio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immunitybio over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunitybio. If investors know Immunitybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunitybio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.90)
Revenue Per Share
0.011
Quarterly Revenue Growth
73.463
Return On Assets
(0.56)
The market value of Immunitybio is measured differently than its book value, which is the value of Immunitybio that is recorded on the company's balance sheet. Investors also form their own opinion of Immunitybio's value that differs from its market value or its book value, called intrinsic value, which is Immunitybio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunitybio's market value can be influenced by many factors that don't directly affect Immunitybio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunitybio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunitybio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunitybio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Immunitybio Number Of Shares Shorted vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Immunitybio's current stock value. Our valuation model uses many indicators to compare Immunitybio value to that of its competitors to determine the firm's financial worth.
Immunitybio is currently regarded as number one stock in operating margin category among its peers. It also is currently regarded as number one stock in number of shares shorted category among its peers . At this time, Immunitybio's Operating Profit Margin is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunitybio's earnings, one of the primary drivers of an investment's value.

Immunitybio Number Of Shares Shorted vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Immunitybio

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
(13.14) %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Immunitybio

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
52.05 M
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Immunitybio Number Of Shares Shorted Comparison

Immunitybio is currently under evaluation in number of shares shorted category among its peers.

Immunitybio Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Immunitybio, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immunitybio will eventually generate negative long term returns. The profitability progress is the general direction of Immunitybio's change in net profit over the period of time. It can combine multiple indicators of Immunitybio, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income10 K10.5 K
Operating Income-362.2 M-344.1 M
Income Before Tax-583.9 M-554.7 M
Total Other Income Expense Net-221.6 M-210.6 M
Net Loss-583.2 M-554 M
Income Tax Expense-40 K-42 K
Interest IncomeM1.9 M
Net Loss-374.9 M-356.2 M
Net Interest Income-123.6 M-117.5 M
Net Loss-458.8 M-481.7 M
Non Operating Income Net Other-2.2 M-2.3 M
Change To Netincome33.4 M25.1 M
Net Loss(1.15)(1.20)
Income Quality 0.63  0.49 
Net Income Per E B T 1.00  1.10 

Immunitybio Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Immunitybio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immunitybio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immunitybio's important profitability drivers and their relationship over time.

Use Immunitybio in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunitybio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunitybio will appreciate offsetting losses from the drop in the long position's value.

Immunitybio Pair Trading

Immunitybio Pair Trading Analysis

The ability to find closely correlated positions to Immunitybio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunitybio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunitybio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunitybio to buy it.
The correlation of Immunitybio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunitybio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunitybio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunitybio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Immunitybio position

In addition to having Immunitybio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Beer and Liquor Thematic Idea Now

Beer and Liquor
Beer and Liquor Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Beer and Liquor theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beer and Liquor Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.